Intern
    Onkologische Forschung

    Svenja Meierjohann:
    Melanoma Signal Transduction

    Summary

    Our group works on oncogenic signaling in melanocytes and melanoma cells and the identification of factors that are required for early steps in melanoma formation. Our main focus lies on the role of the cysteine supply in melanoma biology as well as melanoma evolution under therapy pressure, with the ultimate aim of identifying essential non-redundant targets for therapeutic intervention.
     

    Recent Publications

    Meierjohann S: Crosstalk signaling in targeted melanoma therapy. Cancer Metastasis Rev. doi: 10.1007/s10555-017-9659-z. (2017) (epub ahead of print)

    Leikam C, Hufnagel AL, Otto C, Murphy DJ, Mühling B, Kneitz S, Nanda I, Schmid M, Wagner TU, Haferkamp B, Bröcker EB, Schartl M, Meierjohann S: In vitro evidence for senescent multinucleated melanocytes as a source for tumor-initiating cells. Cell Death Dis 6:e1711 (2015)

    Schmitt A, Schmitz W, Hufnagel A, Schartl M, Meierjohann S: Peroxiredoxin 6 triggers melanoma cell growth by increasing arachidonic acid-dependent lipid signalling. Biochem J 471:267-279 (2015)

    Leikam C, Hufnagel A, Walz S, Kneitz S, Fekete A, Müller MJ, Eilers M, Schartl M, Meierjohann S: Cystathionase mediates senescence evasion in melanocytes and melanoma cells. Oncogene 33:771-782 (2014)

    Haferkamp, S., Borst, A., Adam, C., Becker, T.M., Motschenbacher, S., Windhövel, S., Hufnagel, A.L., Houben, R., Meierjohann, S. (2013) Vemurafenib induces senescence features in melanoma cells. J Invest Dermatol. doi: 10.1038/jid.2013.6.

    Kontakt

    Comprehensive Cancer Center
    Haus C16
    Josef-Schneider Str. 6
    97080 Würzburg

    Tel.: +49 931 201-35350
    Fax: +49 931 201-35359
    E-Mail

    Suche Ansprechpartner

    Campus Medizin